Posted by Michael Wonder on 09 May 2025
Osimertinib mesylate in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy for patients with advanced EGFR mutation positive non-small-cell lung cancer (final guidance)
8 May 2025 - Osimertinib mesylate, when used in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy, is recommended as an option for the first-line treatment of adults with advanced non-small-cell lung cancer whose tumours have an EGFR exon 19 deletion or an exon 21 (L858R) substitution mutation
The combination of osimertinib mesylate and pemetrexed disodium heptahydrate and platinum-based chemotherapy is only recommended if AstraZeneca provides osimertinib mesylate according to the commercial arrangement.
